病例报告:当双重免疫检查点封锁反击时:在固体瘤中引起的cadonilimab过敏症 - 一个案例系列和综述
Ping Song1, Yuqi Jin2,3,4,5, Linglin Fu6
1Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Frontiers in immunology
|August 27, 2025
概括
卡多尼利马布是一种双特异性抗体,在固体瘤中显示出有效性,但可能引起过敏反应. 及时处理这些与免疫相关的不良事件可以继续治疗.
科学领域:
- 癌症学
- 免疫疗法
- 临床医学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗.
- 免疫相关的过敏反应是ICI的一个问题.
- 卡多尼利马布是一种PD- 1/ CTLA- 4双特异性抗体,具有抗瘤功效,但可能导致过敏.
研究的目的:
- 报告卡多尼利马布引起的过敏反应.
- 审查卡多尼利马布在固体瘤中的疗效和安全性.
- 强调及时识别和管理不良事件.
主要方法:
- 五名患者的病例系列经历了cadonilimab诱导的反应.
- 从轻微的皮疹到过敏反应的临床表现记录.
- 对cadonilimab试验,病例报告和现实世界的证据的文献综述.
主要成果:
- 观察到的反应范围从皮疹到严重的过敏反应.
- 个性化的抗过敏干预措施是有效的.
- 修改后的输液方案使得一些患者能够安全地继续治疗.
结论:
- 卡多尼利马布引起的过敏反应是一种可控的风险.
- 早期检测和量身定制的治疗对于安全使用cadonilimab至关重要.
- 卡多尼利马布的临床应用得到了适当的监测和管理策略的支持.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.5K
15:24Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
3.3K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
01:30Drug Toxicity: Allergic Reactions
223
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
223